Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab + Nab-Paclitaxel + Gemcitabine in CLDN18.2+ Metastatic Pancreatic Cancer
NCT03816163Phase 2Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- Mar 2019
- Primary completion
- Oct 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of zolbetuximab in pancreatic adenocarcinoma (PDAC), sponsored by Astellas Pharma. Started Mar 2019; status: active, not recruiting.
02
Drugs
zolbetuximab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03816163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03816163.